UNITY Biotechnology to host in-person and virtual Ophthalmology Day
The event will focus on UNITY’s ongoing Phase 2b ASPIRE study, which is evaluating foselutoclax (UBX1325) head-to-head against aflibercept in DME.
(Image credit: AdobeStock/Rawpixel.com)
UNITY Biotechnology, Inc. is set to host an in-person and virtual event for investors and analysts on Tuesday, October 15, 2024.
The event will focus on UNITY’s ongoing Phase 2b ASPIRE study, which is evaluating foselutoclax (UBX1325) head-to-head against aflibercept in diabetic macular edema (DME). Along with the data being presented during the scheduled event, the 24-week safety and efficacy data are expected in the first quarter of 2025. Further reporting is set to include 36-week data, which are expected in the second quarter of 2025.
According to a press release from the company, the agenda for the event is as follows:
Day: Tuesday, October 15, 2024
Time: 8:00 am until 9:30 am ET
Location: Park Terrace Hotel, New York, NY (with simultaneous webcast)
Registration and Webcast: https://lifescievents.com/event/unitybiotechnology/
- Welcome and Introductions: Anirvan Ghosh, PhD, Chief Executive Officer, UNITY Biotechnology
- Senolytic Therapeutic Hypothesis: Mike Sapieha, PhD, Chief Scientist, UNITY Biotechnology
- UBX1325 Clinical Development Plan – BEHOLD and ASPIRE studies in DME: Robert Bhisitkul, MD, PhD, UCSF School of Medicine
- Retina Expert Roundtable:
- Arshad Khanani, MD, MA, FASRS, Sierra Eye Associates, University of Nevada Reno School of Medicine
- Dante Pieramici, M.D., California Retina Consultants
- Alicia Tozier, Chief Strategy Officer, UNITY Biotechnology
- Live Q&A
Archived replays will be available for 90 days following the event on the company's website.
